IP Library › Granted Patent US 7,485,297
Granted Patent B2
US 7,485,297 · App. 11/199,739 · Granted Feb 3, 2009

Method of inhibition of vascular development using an antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,485,297
App. No.
11/199,739
Granted
Feb 3, 2009
Kind
B2
Abstract

Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The agents can be used to treat angiogenesis-associated disorders.

Claims (39)

1. A method of inhibiting vascular development in a subject, the method comprising

administering, to a subject an isolated Tie1 binding protein, wherein the protein comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the protein binds to Tie1 ectodomain and

(A) the heavy chain immunoglobulin variable domain sequence comprises the following properties:

i) a HC CDR1 that includes (AGSIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ ID NO:118);

ii) a HC CDR2 that includes (GSV)-I-(SY)-P-S-G-G-(WNQ)-T-(GY) (SEQ ID NO:160); and

iii) a HC CDR3 that includes A-P-R-G-Y-S-Y-G-Y-Y-Y (SEQ ID NO:157); and

(B) the light chain immunoglobulin variable domain sequence comprises the following properties:

i) a LC CDR1 that includes R-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN)-(STIRH)-X1-(SYWNH)-(LV)-(ASN) (SEQ ID NO:132), wherein X1 can be serine or absent;

ii) a LC CDR2 that includes (AGTKDEH)-A-S-(STN)-(LR)-(AVEQ)-(ST) (SEQ ID NO:136); and

iii) a LC CDR3 that includes Q-Q-F-N-S-Y-P-H (SEQ ID NO:158).

2. The method of claim 1 wherein the agent is administered in an amount or a time effective to decrease vascular development in a subject.

3. The method of claim 1 wherein the subject has a vasculature-dependent cancer or tumor.

4. The method of claim 3 wherein the tumor is a solid tumor.

5. The method of claim 1 further comprising providing a second therapy that is an anti-cancer therapy.

6. The method of claim 5 wherein the second therapy is a chemotherapeutic.

7. The method of claim 5 wherein the second therapy comprises administering an agent that antagonizes signaling through a VEGF pathway.

8. The method of claim 5 wherein the second therapy comprises administering bevacizumab.

9. The method of claim 5 wherein the second therapy comprises administering 5-FU, leucovorin, or irinotecan.

10. The method of claim 1 , wherein the protein inhibits tube formation by HUVEC cells in vitro.

11. The method of claim 1 , wherein the protein is a Fab.

12. The method of claim 1 , wherein the protein is an IgG.

13. The method of claim 1 , wherein the amino acid sequences of the HC variable domain sequence comprise residues 31-35 of SEQ ID NO:114, residues 50-66 of SEQ ID NO:114, and residues 99-109 of SEQ ID NO:114, and the LC variable domain sequence comprises residues 24-34 of SEQ ID NO:116, residues 50-56 of SEQ ID NO:116, and residues 89-96 of SEQ ID NO:116.

14. The method of claim 1 , wherein the protein comprises SEQ ID NO:114.

15. The method of claim 1 , wherein the protein comprises SEQ ID NO:116.

16. The method of claim 1 , wherein the protein comprises SEQ ID NOS: 114 and 116.

17. The method of claim 1 , wherein the protein comprises residues 1-141 of SEQ ID NO:701.

18. The method of claim 1 , wherein the protein comprises SEQ ID NO:159.

19. The method of claim 1 , wherein the protein comprises residues 1-141 of SEQ ID NO:701 and SEQ ID NO:159.

20. The method of claim 1 , wherein the protein comprises SEQ ID NO:701.

21. The method of claim 1 , wherein the protein comprises SEQ ID NO:700.

22. The method of claim 1 , wherein the subject has colon cancer.

23. The method of claim 1 , wherein the subject has rectal cancer.

24. The method of claim 1 , wherein the subject has renal cell cancer.

25. The method of claim 1 , wherein the subject has liver cancer.

26. The method of claim 1 , wherein the subject has lung cancer.

27. The method of claim 26 , wherein the lung cancer is non-small cell lung cancer.

28. The method of claim 1 , wherein the subject has breast cancer.

29. The method of claim 1 , wherein the subject has prostate cancer.

30. The method of claim 1 , wherein the subject has ovarian cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →